Reading LAB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LAB free→Reading LAB? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LAB free→QuarterlyIQ Insights · LAB
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Changes in Control of Registrant. To the extent required by this Item, the information included in
Unregistered Sales of Equity Securities. Certain of the shares of Standard BioTools Common Stock being issued in the Merger will be issued in private placements exempt from registration under Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder, because the offer and sale of such securities does not involve a “public offering” as defined in Section 4(a)(2) of the Securities Act. Neither this Current Report on Form 8-K nor any of the exhibits attached hereto is an o…
The excerpt does not provide specific details about a management change.
Entry into a Material Definitive Agreement. Merger Agreement On June 6, 2026, Standard BioTools Inc., a Delaware corporation (“Standard BioTools”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Treeline Biosciences, Inc., a Delaware corporation (“Treeline”), and Siri Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Standard BioTools (“Merger Sub”), pursuant to which Standard BioTools and Treeline will combine in an all-s…
Regulation FD Disclosure. On June 8, 2026, Standard BioTools and Treeline issued a joint press release announcing the execution of the Merger Agreement (the “Press Release”), and Standard BioTools included prepared remarks and an investor presentation on its website. On June 8, 2026, Standard BioTools conducted a town hall for its employees related to the Transactions. Copies of the Press Release, the prepared remarks, the investor presentation and the town hall presentation are attached as E…
Sean Mackay: Compensatory arrangement of restricted stock units granted to an existing officer.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 2026 Change of Control and Severance Plan On May 21, 2026, the Board of Directors (the “Board”) of Standard BioTools Inc. (the “Company”) approved the Company’s 2026 Change of Control and Severance Plan and Participation Agreement thereunder (the “2026 Severance Plan”). The 2026 Severance Plan has a term until August 4, 2028. The 2026 Severance Pla…
Results of Operations and Financial Condition On May 5, 2026, Standard BioTools Inc. issued a press release which included information with respect to certain financial results for the three months ended March 31, 2026. The press release is attached hereto as Exhibit 99.1. The information set forth in the press release, except for the information set forth under the headings “Full Year 2026 Revenue Outlook” and “About Standard BioTools Inc.”, together with the forward-looking statement discla…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On April 20, 2026, Standard BioTools Inc. (NASDAQ: LAB) (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (the “Nasdaq”) indicating that the Company did not meet the minimum bid price requirement set forth in Nasdaq’s Listing Rules for continued listing on The Nasdaq Global Select Market. The Not…
Results of Operations and Financial Condition On February 24, 2026, Standard BioTools Inc. issued a press release which included information with respect to certain financial results for the three months and fiscal year ended December 31, 2025. The press release is attached hereto as Exhibit 99.1. The information set forth in the press release, except for the information set forth under the headings “Full Year 2026 Revenue Outlook” and “About Standard BioTools Inc.”, together with the forward…
Regulation FD Disclosure. On January 30, 2026, the Company issued the Press Release announcing the completion of the Transaction. A copy of the Press Release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. The information set forth in Items 2.02 and 7.01 and in the attached Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or incorporated by reference in any filing under t…
Completion of Acquisition or Disposition of Assets. On January 30, 2026, Standard BioTools Inc., a Delaware corporation (the “ Company ”) completed the previously announced sale of all of the equity interests of SomaLogic, Inc. (“S omaLogic ”), Sengenics Corporation LLC and Sengenics Corporation Pte Ltd (such equity interests, collectively, the “ Shares ”), the entities that operate the Company’s aptamer-based and functional proteomics business, including KREX, Single SOMAmer and translationa…
Results of Operations and Financial Condition. On January 30, 2026, the Company issued a press release (the “Press Release”), as described further under
Results of Operations and Financial Condition On January 8, 2026, Standard BioTools Inc. (the "Company") issued a press release, which included information with respect to certain preliminary financial results of the Company for the three months and fiscal year ended December 31, 2025. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The Company's preliminary financial results are unaudited and based on current expectations and may be adjusted as a re…
Results of Operations and Financial Condition On November 4, 2025, Standard BioTools Inc. issued a press release which included information with respect to certain financial results for the three and nine months ended September 30, 2025. The press release is attached hereto as Exhibit 99.1. The information set forth in the press release, except for the information set forth under the headings “Operational Restructuring,” “Full Year 2025 Revenue Outlook” and “About Standard BioTools Inc.,” tog…
Costs Associated with Exit or Disposal Activities On September 13, 2025, Standard BioTools Inc. (the “Company”) commenced a restructuring plan, including a reduction-in-force of approximately 15% of its total global workforce. The purpose of this restructuring plan, including the reduction-in-force, is to improve operational efficiency and reduce operating costs of its continuing operations in line with the Company’s current revenue projections, while supporting the execution of the Company’s…
Costs Associated with Exit or Disposal Activities On August 28, 2025, Standard BioTools Inc. (the “Company”) determined to consolidate its South San Francisco-based R&D capabilities into its Singapore facility to co-locate with its manufacturing operations and to implement a reduction-in-force of certain U.S. employees in the Company’s R&D function, including members of its management team. This is part of a plan to restructure the Company’s operating expenses to improve operational efficienc…
Results of Operations and Financial Condition On August 11, 2025, Standard BioTools Inc. issued a press release which included information with respect to certain financial results for the three and six months ended June 30, 2025. The press release is attached hereto as Exhibit 99.1. The information set forth in the press release, except for the information set forth under the heading “Full Year 2025 Revenue Outlook” and under the heading “About Standard BioTools Inc.,” together with the forw…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 29, 2025, the Board of Directors (the “Board”) of Standard BioTools Inc. (the “Company”) approved restricted stock unit (“RSU”) retention awards for Michael Egholm, Ph.D., President & Chief Executive Officer of the Company, and Alex Kim, Chief Financial Officer of the Company, under the Company’s Amended and Restated 2011 Equity Incentive P…
and in the attached Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. Forward-Looking Statements Certain statements made in this Current Report on Form 8-K and Exhibit 99.1 hereto are forward-looking statements within…
Entry into a Material Definitive Agreement. On June 22, 2025, Standard BioTools Inc., a Delaware corporation (the “ Company ”), entered into a Stock Purchase Agreement (the “ Purchase Agreement ”) with Illumina, Inc., a Delaware corporation (“ Purchaser ”). Pursuant to the terms of the Purchase Agreement, Purchaser will acquire all of the equity interests of SomaLogic, Inc., Sengenics Corporation LLC and Sengenics Corporation Pte Ltd (such equity interests, collectively, the “ Shares ”), each…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Standard BioTools Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) on June 18, 2025. The Company’s stockholders voted to approve an amendment to the Company’s Amended and Restated 2011 Equity Incentive Plan, as amended (the “Plan”), increasing the number of shares of common stock reserved for issuance thereun…
Results of Operations and Financial Condition On May 6, 2025, Standard BioTools Inc. issued a press release which included information with respect to certain financial results for the three months ended March 31, 2025. The press release is attached hereto as Exhibit 99.1. The information set forth in the press release, except for the information set forth under the heading “Full Year 2025 Revenue Outlook” and under the heading “About Standard BioTools Inc.,” together with the forward-looking…
Results of Operations and Financial Condition On February 26, 2025, Standard BioTools Inc. issued a press release which included information with respect to certain financial results for the three months and fiscal year ended December 31, 2024. The press release is attached hereto as Exhibit 99.1. The information set forth in the press release, except for the information set forth under the heading “Full Year 2025 Revenue Outlook” and under the heading “About Standard BioTools Inc.,” together…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.